Email this article to a friend
XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy
-
* Corresponding author: H Lubenau heinz.lubenau@t-online.de
BMC Cancer 2008, 8:332 doi:10.1186/1471-2407-8-332